Bafna Pharmaceuticals Limited
NSE:BAFNAPH.NS
81.76 (INR) • At close November 4, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,524.657 | 1,153.499 | 851.404 | 712.179 | 424.725 | 433.589 | 471.707 | 649.615 | 853.184 | 976.749 | 1,853.394 | 1,757.707 | 1,256.621 | 1,019.242 | 751.813 | 472.537 | 396.068 | 372.464 |
| Cost of Revenue
| 1,309.3 | 765.94 | 512.858 | 454.555 | 270.236 | 345.693 | 438.919 | 577.736 | 729.17 | 916.627 | 1,355.88 | 1,329.111 | 980.348 | 859.885 | 629.742 | 356.955 | 367.398 | 351.756 |
| Gross Profit
| 215.357 | 387.559 | 338.546 | 257.624 | 154.489 | 87.896 | 32.788 | 71.88 | 124.014 | 60.122 | 497.514 | 428.596 | 276.273 | 159.357 | 122.072 | 115.582 | 28.67 | 20.708 |
| Gross Profit Ratio
| 0.141 | 0.336 | 0.398 | 0.362 | 0.364 | 0.203 | 0.07 | 0.111 | 0.145 | 0.062 | 0.268 | 0.244 | 0.22 | 0.156 | 0.162 | 0.245 | 0.072 | 0.056 |
| Reseach & Development Expenses
| 15.362 | 7.212 | 14.728 | 13.589 | 10.095 | 7.527 | 3.709 | 7.185 | 8.169 | 9.557 | 11.627 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 193.12 | 14.803 | 15.814 | 7.218 | 12.116 | 5.469 | 7.832 | 4.45 | 29.192 | 111.234 | 15.085 | 21.957 | 0 | 20.379 | 13.608 | 9.504 | 5.386 | 4.99 |
| Selling & Marketing Expenses
| 6.01 | 5.625 | 23.42 | 6.48 | 3.678 | 8.098 | 4.752 | 7.938 | 0.791 | 17.237 | 49.321 | 36.913 | 0 | 11.523 | 7.363 | 4.984 | 3.176 | 4.017 |
| SG&A
| 154.199 | 20.428 | 39.234 | 13.698 | 15.794 | 13.567 | 12.584 | 12.388 | 29.983 | 128.471 | 243.535 | 198.348 | 0 | 31.902 | 20.971 | 14.489 | 8.562 | 9.007 |
| Other Expenses
| 35.224 | 32.727 | 12.609 | 0.074 | 0.075 | 4.08 | 7.565 | 0.053 | 0.055 | 0.055 | 344.07 | 0.12 | 83.196 | 40.104 | 22.828 | 19.227 | 5.668 | 4.505 |
| Operating Expenses
| 154.199 | 283.747 | 274.197 | 196.243 | 174.097 | 159.135 | 160.87 | 164.767 | 153.073 | 251.612 | 344.07 | 283.675 | 138.042 | 61.13 | 53.689 | 63.643 | 9.865 | 3.719 |
| Operating Income
| 61.158 | 117.723 | 66.41 | 61.456 | -19.747 | -162.819 | -128.082 | -203.627 | -153.192 | 60.672 | 24.912 | 54.921 | 138.231 | 98.227 | 68.383 | 51.939 | 18.805 | 16.99 |
| Operating Income Ratio
| 0.04 | 0.102 | 0.078 | 0.086 | -0.046 | -0.376 | -0.272 | -0.313 | -0.18 | 0.062 | 0.013 | 0.031 | 0.11 | 0.096 | 0.091 | 0.11 | 0.047 | 0.046 |
| Total Other Income Expenses Net
| 12.321 | -1.56 | -14.247 | -3.189 | 0.967 | -20.11 | -19.084 | -110.74 | -124.133 | 252.161 | -128.532 | -90 | -84.517 | -50.849 | -28.731 | -27.186 | -5.828 | -5.82 |
| Income Before Tax
| 73.479 | 116.163 | 73.076 | 58.267 | -18.834 | -182.928 | -147.166 | -203.627 | -153.192 | 60.672 | 24.912 | 54.921 | 53.714 | 47.377 | 39.652 | 24.753 | 12.977 | 11.17 |
| Income Before Tax Ratio
| 0.048 | 0.101 | 0.086 | 0.082 | -0.044 | -0.422 | -0.312 | -0.313 | -0.18 | 0.062 | 0.013 | 0.031 | 0.043 | 0.046 | 0.053 | 0.052 | 0.033 | 0.03 |
| Income Tax Expense
| 49.786 | 2.783 | 12.56 | -2.303 | 229.707 | 10.674 | 21.927 | -9.03 | -1.778 | -1.526 | 10.468 | 14.789 | 34.659 | 13.897 | 14.838 | 14.078 | 0.992 | 1.485 |
| Net Income
| 73.479 | 113.38 | 52.163 | 58.267 | -247.293 | -188.704 | -167.365 | -190.868 | -140.269 | 61.774 | 14.036 | 39.627 | 18.408 | 33.481 | 24.813 | 10.675 | 11.985 | 9.685 |
| Net Income Ratio
| 0.048 | 0.098 | 0.061 | 0.082 | -0.582 | -0.435 | -0.355 | -0.294 | -0.164 | 0.063 | 0.008 | 0.023 | 0.015 | 0.033 | 0.033 | 0.023 | 0.03 | 0.026 |
| EPS
| 3.11 | 4.79 | 2.21 | 2.46 | -104.54 | -7.98 | -9.24 | -10.43 | -8.8 | 3.28 | 0.75 | 2.14 | 1.04 | 1.92 | 1.55 | 0.74 | 1.52 | 2.51 |
| EPS Diluted
| 3.11 | 4.79 | 2.21 | 2.46 | -104.54 | -7.98 | -9.24 | -10.43 | -8.8 | 3.28 | 0.75 | 2.14 | 1.04 | 1.92 | 1.55 | 0.74 | 1.52 | 2.51 |
| EBITDA
| 111.112 | 189.883 | 133.251 | 103.935 | 14.113 | -32.824 | -82.245 | -49.036 | 8.496 | -138.022 | 243.383 | 226.094 | 201.259 | 118.027 | 85.404 | 64.268 | 22.262 | 20.096 |
| EBITDA Ratio
| 0.073 | 0.165 | 0.157 | 0.146 | 0.033 | -0.076 | -0.174 | -0.075 | 0.01 | -0.141 | 0.131 | 0.129 | 0.16 | 0.116 | 0.114 | 0.136 | 0.056 | 0.054 |